Cardiovascular disease in metabolic-Associated fatty liver disease

Research output: Contribution to journalReview articlepeer-review


Purpose of reviewFatty liver disease is increasingly common worldwide and is associated with an increased risk of cardiovascular disease (CVD).Recent findingsThis review describes the cardiovascular outcomes, clinical assessment and management as well as the impact of emerging drug treatment on CVD risk.SummaryPatients with fatty liver require CVD risk assessment including consideration of statin therapy. Emerging therapeutic drugs for fatty liver may have both adverse and beneficial effects on CVD risk.

Original languageEnglish
Pages (from-to)81-86
Number of pages6
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Issue number2
Publication statusPublished - 1 Apr 2023


Dive into the research topics of 'Cardiovascular disease in metabolic-Associated fatty liver disease'. Together they form a unique fingerprint.

Cite this